San Diego based Sorrento Therapeutics claims that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration which lead to jumps in stocks around 244%.
Subsidiary of Sun Pharma, Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for USD 8.2 million (approx Rs 61.35 crore).